BIT:PHN • IT0005274094
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for PHARMANUTRA SPA (PHN.MI).
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 82.724M 21.45% | 100.202M 21.13% | 115.498M 15.27% | 133.6M 15.67% | 153.48M 14.88% | 176.55M 15.03% | 199.81M 13.17% | 204.81M 2.50% | 219.58M 7.21% | 233.53M 6.35% | 246.67M 5.63% | 255.12M 3.43% | |
| EBITDA YoY % growth | 24.392M 20.10% | 26.512M 8.69% | 31.575M 19.10% | 34.277M 8.56% | 40.883M 19.27% | 48.68M 19.07% | 42.43M -12.84% | 54.022M 27.32% | 57.644M 6.70% | 61.165M 6.11% | 64.384M 5.26% | 67.301M 4.53% | |
| EBIT YoY % growth | 23.074M 21.95% | 23.388M 1.36% | 27.646M 18.21% | 29.708M 7.46% | 36.087M 21.47% | 43.7M 21.10% | 46.019M 5.31% | 50.515M 9.77% | 53.978M 6.86% | 57.237M 6.04% | 60.292M 5.34% | 62.171M 3.12% | |
| Operating Margin | 27.89% | 23.34% | 23.94% | 22.24% | 23.51% | 24.75% | 23.03% | 24.66% | 24.58% | 24.51% | 24.44% | 24.37% | |
| EPS YoY % growth | 1.56 15.55% | 1.33 -14.74% | N/A 43.02% | 2.03 6.55% | 2.50 23.42% | 3.06 22.48% | N/A | N/A | N/A | N/A | N/A | N/A |
All data in EUR
| Q4 / 25 | |
|---|---|
| EPS Q2Q % growth | 0.63 |
| Revenue Q2Q % growth | 36.865M -37.96% |
| EBITDA Q2Q % growth | 7.878M -53.82% |
| EBIT Q2Q % growth | 6.666M -49.24% |
All data in EUR
7 analysts have analysed PHN.MI and the average price target is 83.98 EUR. This implies a price increase of 12.27% is expected in the next year compared to the current price of 74.8.
PHARMANUTRA SPA (PHN.MI) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of PHARMANUTRA SPA (PHN.MI) is 0.63 EUR and the consensus revenue estimate is 36.87M EUR.
The consensus rating for PHARMANUTRA SPA (PHN.MI) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.